First Cellular Therapy for Advanced Melanoma Succeeds
The FDA approved Amtagvi, the first therapy using patients’ own tumor-infiltrating lymphocytes to fight aggressive melanoma. The treatment extracts and multiplies T cells from patients’ tumors to combat cancer more effectively. Clinical trials showed a 56% response rate, with complete cancer disappearance in 24% of patients. This breakthrough represents a significant advance in personalized cancer treatment, potentially opening new pathways for treating other types of cancer through similar immune cell manipulation.